These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 35251056)

  • 1. Editorial: Autoimmune Diabetes: Molecular Mechanisms and Neoantigens.
    Kent SC; Zaldumbide A
    Front Immunol; 2022; 13():864517. PubMed ID: 35251056
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity.
    Kracht MJL; Zaldumbide A; Roep BO
    Trends Endocrinol Metab; 2016 Jun; 27(6):353-362. PubMed ID: 27094501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioengineering strategies for inducing tolerance in autoimmune diabetes.
    Baekkeskov S; Hubbell JA; Phelps EA
    Adv Drug Deliv Rev; 2017 May; 114():256-265. PubMed ID: 28625830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying immunotherapy for the management of autoimmune diabetes.
    Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
    Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune therapies for autoimmune diabetes targeting pathogenic peptide-MHC complexes.
    Davidson HW; Zhang L
    J Mol Cell Biol; 2020 Jan; 12(10):759-763. PubMed ID: 32663282
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in immunotherapy of type I diabetes.
    Ni Q; Pham NB; Meng WS; Zhu G; Chen X
    Adv Drug Deliv Rev; 2019 Jan; 139():83-91. PubMed ID: 30528629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.
    Cabello-Olmo M; Araña M; Radichev I; Smith P; Huarte E; Barajas M
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus.
    Trucco M; Giannoukakis N
    Expert Opin Biol Ther; 2007 Jul; 7(7):951-63. PubMed ID: 17665986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic basis of immunotherapies for type 1 diabetes mellitus.
    Chen W; Xie A; Chan L
    Transl Res; 2013 Apr; 161(4):217-29. PubMed ID: 23348026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune surveillance: paraneoplastic or environmental triggers of autoimmunity.
    Lernmark A
    Crit Rev Immunol; 1997; 17(5-6):437-47. PubMed ID: 9419431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer.
    Benvenuto M; Focaccetti C; Izzi V; Masuelli L; Modesti A; Bei R
    Semin Cancer Biol; 2021 Jul; 72():65-75. PubMed ID: 31698088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting neoantigens to augment antitumour immunity.
    Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM
    Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
    Kolb H; von Herrath M
    Cell Metab; 2017 Feb; 25(2):233-241. PubMed ID: 27839907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell reactivity to human insulinoma cell line (CM) antigens in patients with type 1 diabetes.
    Monetini L; Cavallo MG; Barone F; Valente L; Russo M; Walker B; Thorpe R; Pozzilli P
    Autoimmunity; 1999; 29(3):171-7. PubMed ID: 10433097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I diabetes mellitus: lessons for human autoimmunity.
    Pugliese A; Eisenbarth GS
    J Lab Clin Med; 1992 Sep; 120(3):363-6. PubMed ID: 1517681
    [No Abstract]   [Full Text] [Related]  

  • 16. The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.
    Fraker C; Bayer AL
    Curr Diab Rep; 2016 Nov; 16(11):109. PubMed ID: 27664042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational development of antigen-specific therapies for type 1 diabetes.
    Fousteri G; Bresson D; von Herrath M
    Adv Exp Med Biol; 2007; 601():313-9. PubMed ID: 17713020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.
    Orabona C; Mondanelli G; Puccetti P; Grohmann U
    Trends Mol Med; 2018 Nov; 24(11):931-941. PubMed ID: 30236470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.
    Gibson VB; Nikolic T; Pearce VQ; Demengeot J; Roep BO; Peakman M
    Clin Exp Immunol; 2015 Dec; 182(3):251-60. PubMed ID: 26206289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Immunotherapy for Type 1 Diabetes.
    Bone RN; Evans-Molina C
    Curr Diab Rep; 2017 Jul; 17(7):50. PubMed ID: 28534310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.